← All trials
NCT02616042
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2009
- Primary completion
- Jul 31, 2009
- Completion date
- Dec 31, 2009
- First posted
- Nov 26, 2015
- Last posted
- Nov 30, 2015
- Enrollment
- 33
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- LGLead sponsor
- Seoul National UniversityCollaborator
- Seoul National UniversityOverall official - principal investigator
- Seoul National UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.